학술논문

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
Document Type
Article
Source
In Blood Advances 22 February 2022 6(4):1152-1161
Subject
Language
ISSN
2473-9529